Syntara Ltd
Syntara Ltd is a biotechnology and medical research company operating in the healthcare sector, primarily engaged in pharmaceuticals and medical research.
Business. Syntara Ltd (SNT.AX) is an industrial company operating within the diversified electrical components industry. The firm generates revenue through the sale of products. Specific details regarding its operating segments and geographic presence are not available. The company is primarily listed on the Australian Securities Exchange.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Syntara Ltd (SNT.AX) is an industrial company operating within the diversified electrical components industry. The firm generates revenue through the sale of products. Specific details regarding its operating segments and geographic presence are not available. The company is primarily listed on the Australian Securities Exchange.
- Syntara Ltd has a basic and diluted share count of 1,876,980,111, indicating no immediate dilution pressure.
- The company's liquidity risk remains unassessed due to the absence of balance-sheet inputs.
- Profitability and return metrics are not available, making it difficult to compare against industry benchmarks.
- Analysts have provided a mean price target of 0.12 AUD, but there is no clear consensus on the company's future performance.
- The company's revenue concentration and geographic exposure are not disclosed, limiting the ability to assess diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue A$7.5M, +37,8% YoY; Operating income +11,9% YoY.
- ▍Revenue A$7.5M, +37,8% YoY
- ▍Operating income +11,9% YoY
- ▍Net income +47,7% YoY
- ▍Free cash flow +10,4% YoY
- ▍Net margin -105.9%
Revenue A$5.4M, −7,9% YoY; Operating income +1,4% YoY.
- ▍Revenue A$5.4M, −7,9% YoY
- ▍Operating income +1,4% YoY
- ▍Net income −33,3% YoY
- ▍Free cash flow −14,7% YoY
- ▍Net margin -279.0%
Revenue A$5.9M, −60,2% YoY; Operating income +7,2% YoY.
- ▍Revenue A$5.9M, −60,2% YoY
- ▍Operating income +7,2% YoY
- ▍Net income −486,8% YoY
- ▍Free cash flow −1 277,7% YoY
- ▍Net margin -192.7%
Revenue A$14.8M, −35,1% YoY; Operating income −247,2% YoY.
- ▍Revenue A$14.8M, −35,1% YoY
- ▍Operating income −247,2% YoY
- ▍Net income +34,8% YoY
- ▍Free cash flow +314,0% YoY
- ▍Net margin -13.1%
Revenue A$22.8M; Operating income -A$4.4M.
- ▍Revenue A$22.8M
- ▍Operating income -A$4.4M
- ▍Net margin -13.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,60 |
| Revenue | —no estimate | —no estimate | 3,2M AUD |
| Operating income | —no estimate | —no estimate | -13,7M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Syntara Ltd Market data — financials · 2026-05-29
- Syntara Ltd Market data — analyst estimates · 2026-05-29
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 27.3%Derived (calculated)
- Net margin (FY 2025-12-31): 8.8%Derived (calculated)
- Gross margin (FY 2025-12-31): 65.5%Derived (calculated)
- Return on equity (FY 2025-12-31): 7.4%Derived (calculated)
- Return on assets (FY 2025-12-31): 5.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.52xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 104.8%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -2.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 27.3%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 4.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 22.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -73.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -22.5%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -19.3%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 1.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 9.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 14.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 5.0%Derived (calculated)
- Revenue (annual): USD 36.37MSEC XBRL filing
- Cost of revenue (annual): USD 12.54MSEC XBRL filing
- Capex (annual): USD 559KSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
- R&D expense (annual): USD 3.35MSEC XBRL filing
- Operating income (annual): USD 3.01MSEC XBRL filing